伊马替尼与干扰素联合治疗慢性粒细胞白血病的疗效分析

目的:探讨伊马替尼与干扰素联合化疗治疗慢性粒细胞白血病(CM L)的疗效。方法:2004年6月—2009年7月新诊断的58例Ph染色体阳性CM L慢性期患者,随机分为伊马替尼组和干扰素联合化疗组,比较两组临床疗效。结果:两组总有效率差异无统计学意义(P>0.05);伊马替尼组完全血液学缓解率,完全细胞遗传学缓解率、完全分子学效应率、5年总生存率均明显高于干扰素联合化疗组(P<0.05)。结论:伊马替尼和干扰素联合化疗都可作为CM L慢性期的有效治疗方法,应依据不同情况实施个体化治疗。

Analysis of the performance of imatinib and interferon combined with chemotherapy for chronic mveloid leukemia

Objective:To investigate the efficacy of imatinib and interferon combined with chemotherapy for chronic myeloid leukemia(CML).Methods:From June 2004 to July 2009,58 patients newly diagnosed CML in chronic phase with philadelphia chromosome positive wererandomly divided into two groups,imatinib group and interferon-chemotherapy group.The clinical effects were compared between the two groups.Results:The total effective rate of two groups was not statistically different(P>0.05).The complete hematologic remission rate,complete cytogenetic remission rate,complete molecular effect rate and 5-year survival rate were higher in the imatinib group than in the interferon-chemotherapy group(P<0.05).Conclusion:Both imatinib and interferon-chemotherapy are effective treatments for CML in chronic phase.Individual treatment scheme should be designed for patients depend on the situation.